androgenetic alopecia
Conditions
Interventions
Test group:subjects received 1 g minoxidil foam twice a day
Control group::Participants received 1 g Men's Rogaine twice daily ?.
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 49 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria Patients must meet all of the following inclusion criteria to be included in this study: 1. Men aged between 18 and 49 years old (including 18 and 49 years old). 2. Male patients who meet the diagnostic criteria for androgenic alopecia: Hamilton Norwood grading of androgenic alopecia is III-V, IV, or V. 3. Willing to use the same shampoo as much as possible during the research period, maintaining the same hairstyle, hair length, and hair color. 4. Willing to cooperate with treatment and visits, willing to accept follow-up, and able to closely cooperate throughout the process. 5. Agree to take effective contraceptive measures during the study period and within 3 months after the last dose. 6. Voluntarily participate in the experiment and sign an informed consent form before the start of the study.
Exclusion criteria
Exclusion criteria: exclusion criteria Patients with any of the following conditions are not eligible for inclusion in this study: 1. Individuals who are known to be allergic to minoxidil or tattoo pigments or have an allergic constitution. 2. History of hypotension (blood pressure below 90 mmHg/60 mmHg). 3. Screening for malignant tumors within the past 5 years (excluding basal cell carcinoma and squamous cell carcinoma in situ in non scalp areas). 4. Suffering from uncontrolled hypertension (using two antihypertensive drugs in the past 3 months, with blood pressure still exceeding 140/90 mmHg). 5. The abnormal electrocardiogram during the screening period has clinical significance as determined by the researchers. 6. Known to have diseases that affect hair growth or interfere with research results (such as human immunodeficiency virus [HIV] infection, connective tissue disease, inflammatory bowel disease, hypothyroidism, etc.). 7. Select treatment drugs (including corticosteroids, estrogens, ketoconazole, etc.) that have been used topically for two consecutive weeks or more within the previous 3 months and may interfere with efficacy evaluation for hair loss sites. 8. Screening for therapeutic drugs (including beta blockers, cimetidine, diazepines, isotretinoin, corticosteroids, vitamin A intake exceeding 10000 IU/day, etc.) that have been administered systemically for two consecutive weeks or more within the previous 3 months and may interfere with efficacy evaluation. 9. Screening for those who have used minoxidil for hair loss in the previous 6 months. 10. Have used 5 a - reductase inhibitors (such as finasteride, dulasteride, etc.) within the 12 months prior to screening. 11. Those who have received chemotherapy, cytotoxic agents, scalp radiation, and/or laser/surgical therapy within the past 12 months prior to screening. 12. Participants who have participated in any other clinical trial studies within the previous 4 weeks of screening (those who have participated in non intervention studies or have only signed informed consent forms (ICFs) and have not received study interventions may be selected). 13. There are hair transplant, hair weaving, or non breathable wigs and hair bonding. 14. Patients with any skin conditions that may interfere with the efficacy evaluation of hair loss, such as fungal or bacterial infections, seborrheic dermatitis, psoriasis, eczema, folliculitis, scars, or scalp atrophy. 15. Select individuals with active hair loss caused by reasons other than androgenic alopecia within the previous 3 months, including diffuse telogen alopecia, alopecia areata, scar alopecia, etc. 16. Other researchers believe that participants are not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Average change of TAHC in the target area; The changes in the self-score of satisfaction of the subjects after treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Average change of TAHC after treatment;The change of the average hair diameter in the target area;The rate of change of TAHC in the target area after treatment;The changes in the ratio of terminal hair to vellus hair in the target area after treatment;The changes in the expert score of full-head hair photography after treatment;The Hamiltonian Norwood classification changes of the subjects after treatment; | — |
Countries
China
Contacts
Public ContactDingquan Yang
China-Japan Friendship Hospital
Outcome results
None listed